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Abstract.  The nucleotide sequence of human throm- 
bospondin (TS) mRNA has been determined from hu- 
man fibroblast and endothelial cDNAs.  The sequence 
of 5802 bp begins  110 bp upstream from the initiator 
codon and includes the entire 3' untranslated region 
(UTR) of the mRNA.  The coding region (3510  bp) 
specifies a protein of 1170 amino acids with all of the 
known features of the TS subunit (Frazier, W.  A. 
1987.  J.  Cell Biol.  105:625-632).  The long 3' UTR of 
2166 nucleotides is extremely A/T-rich, particularly in 
the latter half. It contains 37 TATT or ATTT(A)  se- 
quences that have been suggested as mediators of the 
stability of mRNAs for cytokines, lymphokines, and 
oncogenes (Shaw, G., and R. Kamen.  1986.  Cell.  46: 
659-667).  Another unusual feature of the 3' UTR of 
TS mRNA is a  stretch of 42 nucleotides of which 40 
are thymidines (uridine in the mRNA) including an 
uninterrupted sequence of 26 thymidines. This region 
is flanked by two sets of direct repeats suggesting that 
it may be an insertion element of retrotranscriptional 
origin. Comparison of the 3' untranslated region of TS 
mRNA with the GenBank data base indicates the 
greatest degree of similarity with an or-interferon gene 
which contains a  number of the TATT/ATTT con- 
sensus sites.  The degree of similarity between the TS 
and interferon sequences is the same in regions of the 
interferon gene corresponding to its coding and non- 
coding regions suggesting that most of the TS 3' UTR 
may be derived from an interferon gene or pseu- 
dogene. The features of the TS mRNA 3' UTR provide 
a potential explanation for the rapid regulation of TS 
message observed in cultured cells in response to 
PDGF and suggest that TS is a  member of a  group of 
proteins which are intimately involved in the control 
of cell growth and differentiation. 
T 
nROMBOSPONDIN (TS) j is a modular or multidomain 
adhesive glycoprotein found in platelet alpha granules 
and involved in platelet aggregation (9, 14). The native 
protein  is  a  trimer of identical subunits that consist of a 
globular NH2-terminal  heparin-binding domain of •  25 kD, 
a thin connecting strand region of ,x,50 kD which contains 
the interchain disulfide bonds, and a COOH-terminal globu- 
lar domain which consists of a calcium-binding region (,~30 
kD) and a cell- or platelet-binding domain of '~23 kD (14, 
20). In addition to heparin and similar glycosaminoglycans, 
TS binds collagens (15), the adhesive glycoproteins fibronec- 
tin, laminin, and fibrinogen (21), as well as plasminogen and 
histidine-rich glycoprotein (36). All of these interactions are 
thought to be mediated by the central connecting strand re- 
gion of the subunit (21). The calcium-binding region of TS 
seems to form an extensible hinge so that in the calcium-re- 
plete form this region appears globular, while after chelating 
calcium, it appears as an extension of the thinner connecting 
1. Abbreviations  used in this paper:  TS, thrombospondin; UTR, untrans- 
lated region. 
strand (10, 14). The COOH-terminal cell- and platelet-bind- 
ing domain of TS probably binds to a membrane glycopro- 
tein receptor on platelets and on other cells which adhere to 
TS (1,  14). 
In addition to its presence in platelets, TS is widely dis- 
tributed.  Localization of TS  in  human tissues  using  im- 
munofluorescence methods demonstrates that the protein is 
present in blood vessel, skin, muscle, and glandular epithe- 
lium (43).  TS is synthesized by a variety of cell types in cul- 
ture where its production is inversely related to the degree 
of confluence of the culture (27). An interesting feature of TS 
regulation is its relatively rapid rate of synthesis and degra- 
dation (22),  suggesting an important regulatory function for 
the protein.  Indeed, it has recently been reported that TS 
mRNA  (18, 23)  and protein  (22)  are  rapidly  induced by 
PDGF in vascular smooth muscle cells and that TS mRNA 
appears with a time course comparable to that of protoon- 
cogenes c-myc and c-fos mRNA in these cells (17, 23, 45). 
Furthermore, TS mRNA levels in cells are superinduced by 
PDGF treatment in the presence of protein synthesis inhibi- 
tors, such as cycioheximide (23).  This phenomenon also has 
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including protooncogenes (45). 
To provide a more detailed understanding of the TS subunit 
structure and to begin investigation of the structural basis for 
the regulation of TS expression, we undertook the cloning of 
TS cDNA from human fibroblasts and endothelial cells. We 
initially reported amino acid sequences from the amino ter- 
mini of the major proteolytic fragments or domains of TS 
that allowed the ordering of these domains within the TS 
polypeptide chain (14). Using amino acid sequence data ob- 
tained on tryptic peptides of TS, we isolated and sequenced 
a human fibroblast cDNA clone designated 6A (Fig.  1) en- 
coding the signal peptide, heparin binding domain, and part 
of the collagen binding region of TS (11). This sequence was 
verified by the presence of the known NH2-terminal amino 
acid sequence of the mature TS subunit as well as five addi- 
tional peptide sequences that we had determined. Lawler and 
Hynes (20) later reported the sequence of human endothelial 
cDNA encoding the TS subunit coding region and a portion 
of the 3' untranslated region (UTR), and Kobiyashi et al. (18) 
reported the sequence of human endothelial cDNA encoding 
the first one-third of the TS peptide chain.  We report here 
the isolation and characteriztaion of two cDNA clones, one 
of which encodes the entire mature TS subunit and a portion 
of the 3' UTR of the mRNA  while the other overlapping 
clone extends to the poly A tail of the mRNA. The sum of 
this information provides a detailed picture of the structure 
of the TS subunit and suggests a potential explanation for the 
regulatory properties of TS mRNA noted above. 
Materials and Methods 
Materials and procedures used in DNA cloning and Sanger dideoxynucleo- 
tide sequencing were generally those reported previously (11). Clone S10 
was isolated from a human fibroblast cDNA library in pUC  19, the con- 
struction of which has been described (11). In sequencing clone S10, we em- 
ployed synthetic oligodeoxynucleotide primers in conjunction with single- 
and double-stranded templates. The Klenow fragment of DNA polymerase 
and AMV reverse transcriptase were purchased from New England Biolabs 
(Boston, MA) and Bethesda Research Laboratories (Gaithersburg, MD). 
Sequenase T7  polymerase was  from  United States Biochemicals Corp. 
(Cleveland, OH). To provide internal starting sites for sequencing, the Pvu 
II fragments of SI0 (see Fig.  1) were used as sequencing primers. Before 
loading the reactions on gels, each reaction was cut with Pvu II to release 
the  extended  labeled  oligonucleotides  from  the  restriction  fragment 
primers. Clone TXE was isolated from a hgtll cDNA library of human um- 
bilical vein endothelial cells prepared by Dr. Evan Sadler of this institution, 
and overlaps the 3' end of S10 by '~450 nucleotides. TXE was identified by 
hybridization with labeled SI0 insert. The Xba l/Eco RI fragment of the 
insert was cloned into Bluescript (Stratagene, San Diego, CA), and sequenc- 
ing was performed using single-stranded templates prepared by superinfec- 
tion with R408 helper phage (Stratagene) and synthetic primers. Data han- 
dling and analysis of sequence data were performed using a MICROVAX 
II computer system and the programs of Compugene (St. Louis, MO) and 
the FASTN program. 
RNA was extracted from human JY fibroblasts (8), both from untreated 
cells grown in medium containing 15% FBS and from cells maintained in 
low serum for 3 d and then treated with PDGF (t0 ng/ml) for 4 h or with 
cyclobeximide (10 ~tg/ml) for 30 min (or with both by adding cycloheximide 
30 min before incubation with PDGF). The RNA was separated on a 0.8% 
agarose/2.2 M formaldehyde gel and was transferred to a Nitroplus 2,000 
membrane (Micron Separations, Inc., Westborough, MA) and hybridized 
and washed as described (26). Probes were radioactively labeled with 32p 
using the random hexanucleotide primer method (13).  A construct desig- 
nated 6S was made by cloning the Sac l/Nsi I fragment of the 6A insert and 
the Nsi I/Xba I fragment of S10 into the Bluescript vector. This insert con- 
tains the entire TS coding region plus 120 nucleotides 5' to the ATG start 
codon. Clone 6SXE was constructed by ligating  the insert of TXE excised 
with Xba I and Kpn I, into Bluescript clone 6S cut with the same enzymes. 
This clone extends 6S through the poly A tail. In vitro transcripts were made 
from 6S and TXE using phage T3 RNA polymerase, and this RNA was in- 
cluded on the RNA gels as a standard. 
Results and Discussion 
We initially reported the isolation of a cDNA clone desig- 
nated 6A (see Fig.  1) encoding the NH2-terminal heparin- 
binding domain of TS (11). Using this cDNA as a probe, 
we have isolated from the same human fibroblast library a 
cDNA clone containing an open reading frame that encodes 
the entire sequence of the TS subunit plus ,~800 nucleotides 
of the 3' untranslated region of its mRNA (clone $10 in Fig. 
1). In an effort to clone the entire 3' UTR of the mRNA, we 
also screened a human endothelial cell cDNA library con- 
structed in Xgtl 1 and recovered a clone extending from with- 
in the 3' end of $10 to a 65 nucleotide poly A sequence (clone 
TXE; Fig. 1). Also indicated in Fig. 1 is a schematic diagram 
of the TS protein subunit based on the translated amino acid 
sequence shown in Fig. 2 in the single letter code. The amino 
acid sequence and its relationship to the domain structure of 
TS along with implied evolutionary relationships with other 
proteins have been discussed elsewhere (14,  20).  The TS 
peptide chain consists of eight discrete regions of protein 
structure, many of which show relatedness to previously se- 
quenced proteins. This suggests that the "IS gene has been 
assembled from a variety of exons "borrowed" from a num- 
ber of ancestral genes such as those which gave rise to the 
present day genes for type I collagen, malarial cell surface 
proteins, the complement protein properdin, epidermal growth 
factor, and calcium-binding proteins (14,  20). 
Fig. 2 shows the nucleotide sequence derived from clones 
6A, S10, and TXE. The initiation codon is embedded in a 
perfect match of the Kozak consensus sequence (11) (boxed 
in Fig. 2). The open reading frame is 3,510 nucleotides long 
and is preceded by 126 nt of 5' untranslated sequence. It is 
followed by another 2,101 nucleotides of 3' untranslated se- 
quence and a poly A tract of 65 nucleotides. This yields a 
total of 5,802 nucleotides, of which 12-15 at the 5' end of the 
sequence represent a homopolymeric C tail added during the 
construction of the library. This value of 5.8 kb is in good 
agreement with estimates of 5.5  (23) to 6.0 (18, 20, 29) kb 
for the mRNA size obtained from Northern blots (Fig. 3). 
Hence,  it is likely that there are very few 5' untranslated 
nucleotides preceding the "~120 nucleotides which are repre- 
sented in clone 6A. 
Recently TS has been found to be a member of a class of 
growth-related proteins whose mRNAs  respond rapidly to 
induction by growth factors, specifically PDGF (17, 18, 23, 
45). TS mRNA levels in rat aortic smooth muscle cells are 
inversely related to the degree of confluency of the culture, 
being highest in sparse cell populations (23). Treatment of 
quiescent cells with either serum or PDGF results  in the 
rapid induction of TS mRNA with a time course similar to 
that of the induction of c-myc mRNA in the same cells (17, 
18, 23). Further, inhibition of protein synthesis with cyclo- 
heximide during induction causes a  larger increase in the 
amount of TS mRNA than found with PDGF alone (23). 
This behavior is characteristic of  mRNAs for several proteins 
which respond to PDGF induction (17, 45), as well as several 
cytokines and lymphokines such as interleukins, interferons, 
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Figure 1.  Alignment of the three cDNAs used in 
deriving  the  complete  TS  mRNA sequence  are 
shown at the top. Restriction sites referred to are 
indicated along with the termination codon (TAA). 
Below the cDNA clones, a schematic diagram of 
the TS mRNA is shown with the  start and  stop 
codons marked. Vertical marks to the right of the 
termination  codon  UAA  indicate  the  sequence 
TATT or ATTT(A); octamer denotes the sequence 
TTATTTAT.  The poly T and poly A sequences dis- 
cussed in the text are also indicated as solid boxes. 
The TS polypeptide chain is diagramed at the bot- 
tom of the figure. Letters below the bar identify 
different regions of structure, arrows above indicate known TS peptide sequences, and arrowheads below point to potential N glycosylation 
sites. The RGDA sequence and the single free sulfhydryl group (SH) are shown. See reference  14 for details of the protein sequence. 
tumor necrosis  factor,  colony  stimulating  factors and  on- 
cogenes such as myc, fos, and myb (17, 32, 35, 45). In addi- 
tion to rapid induction, this group of mRNAs also undergoes 
rapid degradation, a property thought to be mediated by A/T- 
rich sequences within the 3' UTR of each mRNA. These se- 
quences, identified as ATTT(A) (35), TATT (32), and TTA- 
TTTAT (5) by different workers, occur multiple times in the 
3' UTR of TS mRNA, being grouped within the latter half 
of the  3' UTR (Figs.  1 and 2).  The oligomers TATT and 
ATTT(A) occur 22 and 27 times, respectively, within the 3' 
UTR,  while the longer octamer sequence TTATTTAT ap- 
pears only once as it does in many of the cytokine and lym- 
phokine cDNAs (5). 
The TS sequence that we have characterized was isolated 
from human fibroblast and endothelial cell cDNA libraries, 
while most of the data regarding TS induction and turnover 
has been obtained in smooth muscle cells. Yet it seems likely 
that the structure of TS mRNA is the same in all cells thus 
far examined, since the size of the major mRNA identified 
on Northern blots is identical in rat smooth muscle cells and 
human fibroblasts (references 23, 29 and Fig.  3).  To ascer- 
tain that the human fibroblast mRNA contained the same 3' 
UTR as the human endothelial cells, a Northern blot of JY 
fibroblast RNAs obtained from cultures grown to different 
cell densities and with or without PDGF treatment was probed 
with the insert derived from clone S10, which contains the 
full length coding region for TS. This established that human 
fibroblasts do indeed contain a predominant mRNA species 
of 6.0 kb in length containing the TS coding sequences (Fig. 
3).  This  blot  was  then  stripped  at  high  temperature  and 
reprobed with the insert of clone TXE which had been de- 
rived from the human endothelial library and contains only 
the extreme 3' UTR region.  As seen in Fig.  3 A, the same 
6 kb band is identified by both probes in all cases.  Lane S 
contains the in vitro transcript from the insert of 6S and pro- 
vides a control for the stripping procedure since the 6S tran- 
script (i.e., the coding region) does not overlap with TXE 
(i.e., the 3' UTR) used to reprobe the blot. In several experi- 
ments, a smaller mRNA band of ~,4.0--4.5 kb was visualized 
in the human fibroblasts after hybridization with the 6S cod- 
ing region probe (Fig. 3, A and B). Similar results were seen 
with RNA extracted from HEL cells, HT1080 cells, and rat 
smooth muscle cells (not shown), suggesting that the smaller 
mRNA species may represent a specific processing or degra- 
dation product. This appears to be the case for JY ceils since 
the smaller RNA band is not detected with a probe prepared 
from the insert of TXE which represents the most 3' portion 
of the mRNA (Fig. 3, A and B). Only the larger RNA hybrid- 
izes with these 3' sequences. Given the potential regulatory 
function of the latter half of the 3' UTR of TS mRNA, the 
finding that cells contain a form of the mRNA missing this 
region is of interest. At present the mode of generation of the 
smaller form of TS mRNA is not known. 
Another unusual feature of the 3' UTR ofTS mRNA is the 
occurrence of a string of 42 nucleotides of which 40 are T 
residues (U in the RNA) including a homopolymer run of 26 
T residues. This poly T run ends  163 nucleotides from the 
beginning of the poly A  tail.  The region bracketed by the 
poly T and poly A tracts could not be sequenced until part 
of the poly A tail was deleted resulting in disruption of the 
base pairing between these two homopolymeric regions in 
the single-stranded template DNA. TS is only the 12th exam- 
ple of an mRNA containing a poly U tract of 10 nucleotides 
or longer in the 3' UTR. Other mRNAs with poly U tracts 
in their 3' UTRs include those for the human insulin receptor 
(42),  chick procollagen type II (34),  bovine acetylcholine 
receptor/3-chain (39), mouse urokinase plasminogen/tctiva- 
tor (2), human/3-actin (40),  chick ovalbumin Y  gene (16), 
human  tissue  factor (37),  and  human  cap-binding protein 
(33). In none of these cases is there a known function for the 
poly U tract (19);  however, it has been suggested that these 
tracts occur as part of insertion elements since they are al- 
ways flanked by direct repeats of 6-11 nucleotides in length 
(44). The long poly U tract in the 3' UTR of the TS mRNA 
is also flanked by two sets of direct repeats. It was recently 
reported that the mRNA  for laminin B2  chain contains  a 
similar sequence element in the 3' UTR of the message (12). 
Interestingly, this laminin mRNA contains 22 of the TATT/ 
ATTT(A) sequence elements and one octamer sequence in 
its 3' UTR and these are clustered in its latter half. One expla- 
nation for these long poly U tracts in UTRs of mRNAs is that 
the gene has had a retroposon inserted in the antisense orien- 
tation  such that its poly A  tail  is transcribed in the sense 
strand as a poly T tract, or a poly U tract in the mRNA. This 
may explain the occurrence of the poly T tract in the TS gene 
since it is followed after 18 nucleotides by a  TTTACT se- 
quence  whose  complement reads  AGTAAA,  a  5/6  match 
with the polyadenylation signal consensus AATAAA. 
Whatever the origin of the long poly U tract in the mRNA, 
it is quite clear that it can hybridize with the poly A  tract 
forming a loop of some 163 nucleotides. Perhaps this duplex 
region  plays  some  role  in  stabilization  of the  TS  mRNA 
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 Figure  3.  Northern blots  of JY human 
fibroblast RNA preparations probed with 
labeled  insert from clone 6S (left)  and 
the  same  blots  stripped  and  reprobed 
with  the  labeled  insert  of clone  TXE 
(right).  (A)  Lane 1 contains  RNA from 
cells grown normally. Lanes 2-5 contain 
RNA from cells  maintained  in low se- 
rum before treatment  as follows: lane 2, 
none  (quiescent  control);  lane  3,  plus 
cycloheximide;  lane 4, plus PDGF; lane 
5,  plus both PDGF and cycloheximide 
(see Materials and Methods for details). 
Lanes 1 and 3-5 contain  10 #g RNA, 
and lane 2 contains  4/~g. Lane S is the 
in vitro transcript  from S10 included  as 
a stripping  control. It is not visualized 
after probing with TXE sequences.  (B) 
Lanes 1-3 represent three different prep- 
arations  of RNA from JY cells  grown 
normally.  Lanes $1 and $2  contain  the 
6S and TXE in vitro transcripts,  respec- 
tively. All lanes  contain  10/zg RNA. 
against 3' exonucleolytic attack as has been proposed for bac- 
terial and histone mRNAs (4, 30). The loop in the TS mRNA 
would contain seven of the TATT/ATTT sequences. If these 
are in fact sites for single-stranded endonuclease attack, the 
subsequent  exonuclease  digestion  of  the  nicked  mRNA 
would be limited by the duplex region just upstream.  Thus, 
the combination of  a large stem-loop structure containing en- 
donuclease  recognition sites  could be a  way of limiting  or 
coordinating two types of control mechanisms operating on 
mRNA stability. It is becoming increasingly clear that the 3' 
UTRs of messages can play an important role in regulation 
of the expression of the proteins which the messages encode. 
For example, iron regulation of expression of the transferrin 
receptor is mediated by a specific stem-loop structure in the 
3' UTR of that mRNA (6). 
A search of  the GenBank nucleic acid database (3) (release 
The Journal of Cell Biology, Volume  108, 1989  734 52.0)  with  the program FASTN using either the entire 3' 
UTR of the TS eDNA  sequence or the portion contained 
within clone TXE (Fig.  1) revealed that the most related se- 
quences in the primate data base were found in the human 
leukocyte a-interferons which displayed a level of 40-45 % 
identity over the entire length of  the TS 3' UTR. The interfer- 
ons are a multigene family, and the a-interferon region hav- 
ing the most similarity to the TS 3' UTR sequence was region 
L  (41).  The interferon gene family includes a  number of 
pseudogenes (41). The rather evenly distributed relatedness 
between the 3' UTR of TS mRNA and the a-interferon genes 
suggests that the TS 3' UTR may have resulted from the in- 
corporation of a  complete interferon-like pseudogene into 
the TS gene. This mode of evolution is certainly consistent 
with the modular assembly of the TS coding region which 
appears to be an excellent example of exon shuffling (14, 20). 
When 1,756 nucleotides of a-interferon gene region L were 
compared with  100 randomized sequences generated from 
1,748 nucleotides of the TS 3' UTR, the mean aligned score 
was 325 while the aligned score for the bona fide TS 3' UTR 
sequence was 536, or 2.42 standard deviations higher. The 
most A/T-rich region of the TS 3' UTR aligned with the 
A/T-rich part of the a-interferon 3' UTR. This is precisely 
the region of the interferon mRNA which is thought to con- 
rain sequences that specify a rapid turnover for this and other 
mRNAs. A high degree of similarity of the A/T-rich region 
of the TS 3' UTR was also found with the 3' UTRs of the hu- 
man/3- and 3~-interferons, interleukin-2, and B-cell leukemia 
(lymphoma) protooncogene mRNAs.  When  only the  280 
nucleotides representing the most A/T-rich segment of the 
TS 3' UTR were used to probe the GenBank database,  the 
a-interferons were again identified as the best match. Thus, 
the  3'  UTR  of  TS  mRNA  contains  multiple  copies  of 
A/T-rich sequences which have been suggested by others to 
specify rapid turnover. It is thought that these sites provide 
targets  or  recognition sequences  for extremely labile  en- 
donucleases, thus explaining the effects of inhibitors of pro- 
tein synthesis to stabilize these mRNAs (5,  32,  35). 
Interestingly, one of the other mRNAs that displayed the 
highest level of relatedness to the TS 3' UTR was the human 
vitronectin receptor a-subunit mRNA (38). Closer inspec- 
tion of the alignment of these two RNAs revealed that, like 
TS mRNA,  vitronectin receptor mRNA contains a large 3' 
UTR which is extremely rich in the putative target sequences 
TATT and ATTT(A), having 51 of these sites in the portion 
of the 3' UTR that has been sequenced. Thus we suggest that 
the vitronectin receptor mRNA may be regulated in a man- 
ner similar to the TS and cytokine mRNAs. 
The fact that TS mRNA responds rapidly to PDGF induc- 
tion and has a very rapid turnover rate suggests that TS is crit- 
ically involved in the growth response of cells that produce 
it. It has been reported that TS appears in the extracellular 
matrix of only proliferating cells and that providing a sink 
for TS in the form of a monoclonal antibody slows the cells' 
growth rate (24). The well-known inhibitory effect of heparin 
on the growth of smooth muscle cells (7) could also be ex- 
plained by an inhibition of TS association with these cells. 
TS binds to a variety of cell types by association of its NH2- 
terminal heparin-binding domain with cell surface heparin- 
like glycosaminoglycans (28). Taken together, these observa- 
tions suggest that TS may be an essential component of an 
autocrine stimulation pathway triggered by growth factors 
such as PDGE Thus, it is not inconceivable that TS could 
act as an oncogene under the proper circumstances. Abnor- 
mally high or prolonged production of TS triggered by muta- 
tion could lead to a proliferative response that is no longer 
regulated. In this regard, it is interesting that deletion of 67 
bp of  the A/T-rich region of the 3' UTR of the c-fos gene con- 
verts it into a transforming gene (25). It was suggested that 
this effect was due to a stabilization of the fos mRNA and a 
concomitant increase in the cellular content of the protein 
(31). The reverse effect on mRNA stability has been observed 
by grafting the homologous 3' UTR region from the granulo- 
cyte-monocyte colony simulating factor (GM-CSF) mRNA 
onto the normally quite stable/~-globin mRNA  (35).  The 
possibility that cells also contain a significant amount of TS 
mRNA  apparently  lacking the A/T-rich sequences  impli- 
cated in the regulation of RNA stability may mean that, in 
some cases, cells normally produce a highly unstable, and 
hence rapidly regulated form, and a more stable form of a 
message at the same time. Experiments to define the poten- 
tial role of the 3' UTR in determining the stability of TS 
mRNA are in progress. 
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Note Added in Proof: Based on recently published TS genomic DNA se- 
quence and a  determination of the transcription  starting site (Donoviel, 
D.  B., P. Framson, C. E  Eldridge, M. Cooke, S. Kobayashi, and P. Born- 
stein. 1988. J. Biol.  Chem.  263:18590-18593), our eDNA clones reported 
here lack only 66 nucleotides at the 5' end. Thus the total length of the TS 
mRNA is 5,855 nucleotides. 
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